Search
United Therapeutics Corp
UTHRAdd to Watchlist
564.940USD
-4.240-0.74%
Close 05/08, 16:00（ET）Quotes delayed by 15 min
23.98BMarket Cap
19.30P/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-0.74%
5 Days
-0.96%
1 Month
-2.88%
6 Months
+25.85%
Year to Date
+15.94%
1 Year
+83.42%
TradingKey Stock Score of United Therapeutics Corp
Currency: USD Updated: 2026-05-08Key Insights
United Therapeutics Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 639.96.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
United Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
United Therapeutics Corp Highlights
StrengthsRisks
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 36.74% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 3.18B.
Overvalued
The company’s latest PE is 19.30, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 42.65M shares, decreasing 3.36% quarter-over-quarter.
Held by CI Select Canadian Equity Fund
Star Investor CI Select Canadian Equity Fund holds 978.00 shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.70.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
639.960
Target Price
+10.11%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
United Therapeutics Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
United Therapeutics Corp Info
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Ticker SymbolUTHR
CompanyUnited Therapeutics Corp
CEORothblatt (Martine A)
Websitehttps://www.unither.com/
Related Instruments
-2.72%
-0.53%
-0.57%
+0.44%
+0.18%
-0.82%
+0.79%
-2.04%
+0.59%
-3.02%
-0.16%
+1.13%
+0.30%
-0.18%
-2.47%
+0.82%
0.00%
-1.08%
-0.65%
-0.88%Popular Instruments
92.193
-2.977 (-3.13%)
293.320
+5.880 (+2.05%)
215.200
+3.700 (+1.75%)
4714.280
+29.030 (+0.62%)
480.000
+16.090 (+3.47%)
1562.340
+222.380 (+16.60%)
746.810
+100.180 (+15.49%)
400.800
+2.810 (+0.71%)
80800.540
+697.450 (+0.87%)
428.350
+16.560 (+4.02%)
